4CI3
| Structure of the DDB1-CRBN E3 ubiquitin ligase bound to Pomalidomide | Descriptor: | DNA DAMAGE-BINDING PROTEIN 1, PROTEIN CEREBLON, S-Pomalidomide, ... | Authors: | Fischer, E.S, Boehm, K, Thoma, N.H. | Deposit date: | 2013-12-05 | Release date: | 2014-07-16 | Last modified: | 2023-12-20 | Method: | X-RAY DIFFRACTION (3.5 Å) | Cite: | Structure of the Ddb1-Crbn E3 Ubiquitin Ligase in Complex with Thalidomide. Nature, 512, 2014
|
|
4CI1
| Structure of the DDB1-CRBN E3 ubiquitin ligase bound to thalidomide | Descriptor: | DNA DAMAGE-BINDING PROTEIN 1, PROTEIN CEREBLON, S-Thalidomide, ... | Authors: | Fischer, E.S, Boehm, K, Thoma, N.H. | Deposit date: | 2013-12-05 | Release date: | 2014-07-16 | Last modified: | 2024-05-01 | Method: | X-RAY DIFFRACTION (2.98 Å) | Cite: | Structure of the Ddb1-Crbn E3 Ubiquitin Ligase in Complex with Thalidomide. Nature, 512, 2014
|
|
4CI2
| Structure of the DDB1-CRBN E3 ubiquitin ligase bound to lenalidomide | Descriptor: | DNA DAMAGE-BINDING PROTEIN 1, PROTEIN CEREBLON, S-Lenalidomide, ... | Authors: | Fischer, E.S, Boehm, K, Thoma, N.H. | Deposit date: | 2013-12-05 | Release date: | 2014-07-16 | Last modified: | 2024-05-01 | Method: | X-RAY DIFFRACTION (2.95 Å) | Cite: | Structure of the Ddb1-Crbn E3 Ubiquitin Ligase in Complex with Thalidomide. Nature, 512, 2014
|
|
5FQD
| Structural basis of Lenalidomide induced CK1a degradation by the crl4crbn ubiquitin ligase | Descriptor: | CASEIN KINASE I ISOFORM ALPHA, DNA DAMAGE-BINDING PROTEIN 1, PROTEIN CEREBLON, ... | Authors: | Petzold, G, Fischer, E.S, Thoma, N.H. | Deposit date: | 2015-12-09 | Release date: | 2016-02-24 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (2.45 Å) | Cite: | Structural Basis of Lenalidomide-Induced Ck1Alpha Degradation by the Crl4(Crbn) Ubiquitin Ligase. Nature, 532, 2016
|
|
7BQV
| Cereblon in complex with SALL4 and (S)-5-hydroxythalidomide | Descriptor: | 2-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-5-oxidanyl-isoindole-1,3-dione, Protein cereblon, SULFATE ION, ... | Authors: | Furihata, H, Miyauchi, Y, Asano, A, Tanokura, M, Miyakawa, T. | Deposit date: | 2020-03-25 | Release date: | 2020-08-26 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide. Nat Commun, 11, 2020
|
|
7BQU
| Cereblon in complex with SALL4 and (S)-thalidomide | Descriptor: | Protein cereblon, S-Thalidomide, Sal-like protein 4, ... | Authors: | Furihata, H, Miyauchi, Y, Asano, A, Tanokura, M, Miyakawa, T. | Deposit date: | 2020-03-25 | Release date: | 2020-08-26 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide. Nat Commun, 11, 2020
|
|
6H0F
| Structure of DDB1-CRBN-pomalidomide complex bound to IKZF1(ZF2) | Descriptor: | DNA damage-binding protein 1,DNA damage-binding protein 1,DNA damage-binding protein 1,DNA damage-binding protein 1, DNA-binding protein Ikaros, Protein cereblon, ... | Authors: | Petzold, G, Bunker, R.D, Thoma, N.H. | Deposit date: | 2018-07-09 | Release date: | 2018-11-07 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (3.25 Å) | Cite: | Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science, 362, 2018
|
|
6H0G
| Structure of the DDB1-CRBN-pomalidomide complex bound to ZNF692(ZF4) | Descriptor: | DNA damage-binding protein 1,DNA damage-binding protein 1,DNA damage-binding protein 1,DDB1 (DNA damage binding protein 1),DNA damage-binding protein 1,DNA damage-binding protein 1,DNA damage-binding protein 1, Protein cereblon, S-Pomalidomide, ... | Authors: | Bunker, R.D, Petzold, G, Thoma, N.H. | Deposit date: | 2018-07-09 | Release date: | 2018-11-07 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (4.25 Å) | Cite: | Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science, 362, 2018
|
|
8U2E
| Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-3-(3-methylphenyl)-1-oxopropan-2-yl]-1H-indazole-5-carboxamide | Descriptor: | (2S)-6-fluoro-5-[(3S)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]-2-(4-methylpiperazine-1-carbonyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide, 1,2-ETHANEDIOL, CHLORIDE ION, ... | Authors: | Gajewski, S, Clifton, M.C. | Deposit date: | 2023-09-05 | Release date: | 2024-01-31 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies. J.Med.Chem., 67, 2024
|
|
8U2D
| Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-3-(3-methylphenyl)-1-oxopropan-2-yl]-1H-indazole-5-carboxamide | Descriptor: | (3R)-2-[N-(1H-indazole-5-carbonyl)-3-methyl-D-phenylalanyl]-N-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxamide, 1,2-ETHANEDIOL, CHLORIDE ION, ... | Authors: | Gajewski, S, Clifton, M.C. | Deposit date: | 2023-09-05 | Release date: | 2024-01-31 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (1.95 Å) | Cite: | Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies. J.Med.Chem., 67, 2024
|
|
3WX2
| Mouse Cereblon thalidomide binding domain, native | Descriptor: | Protein cereblon, SULFATE ION, ZINC ION | Authors: | Mori, T, Ito, T, Hirano, Y, Yamaguchi, Y, Handa, H, Hakoshima, T. | Deposit date: | 2014-07-10 | Release date: | 2014-08-06 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs Nat.Struct.Mol.Biol., 21, 2014
|
|
3WX1
| Mouse Cereblon thalidomide binding domain, selenomethionine derivative | Descriptor: | Protein cereblon, SULFATE ION, ZINC ION | Authors: | Mori, T, Ito, T, Hirano, Y, Yamaguchi, Y, Handa, H, Hakoshima, T. | Deposit date: | 2014-07-10 | Release date: | 2014-08-06 | Last modified: | 2014-09-17 | Method: | X-RAY DIFFRACTION (1.93 Å) | Cite: | Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs Nat.Struct.Mol.Biol., 21, 2014
|
|
6R0V
| |
6R0U
| Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5a and hydrolysis product | Descriptor: | 3-azanyl-2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]benzoic acid, 4-azanyl-2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]isoindole-1,3-dione, CHLORIDE ION, ... | Authors: | Heim, C, Hartmann, M.D. | Deposit date: | 2019-03-13 | Release date: | 2019-08-07 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives. J.Med.Chem., 62, 2019
|
|
6R0S
| Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 4a and hydrolysis product | Descriptor: | 2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-4-nitro-isoindole-1,3-dione, 2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]-6-nitro-benzoic acid, CEREBLON ISOFORM 4, ... | Authors: | Heim, C, Hartmann, M.D. | Deposit date: | 2019-03-13 | Release date: | 2019-08-07 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.55 Å) | Cite: | De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives. J.Med.Chem., 62, 2019
|
|
6R0Q
| |
6R11
| Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5b | Descriptor: | 5-azanyl-2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]isoindole-1,3-dione, CHLORIDE ION, Cereblon isoform 4, ... | Authors: | Heim, C, Hartmann, M.D. | Deposit date: | 2019-03-13 | Release date: | 2019-08-07 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.75 Å) | Cite: | De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives. J.Med.Chem., 62, 2019
|
|
6R13
| |
6R12
| |
6R18
| |
6R19
| |
6R1A
| |
6R1D
| |
6R1K
| |
6R1W
| |